Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Additionally, the trial met all secondary endpoints, demonstrating significant improvement with semaglutide vs placebo in pain-free walking distance (ETR: 1.11 [95% CI, 1.03-1.20; P =.0046 ...

Overall, patients in the semaglutide arm had a median improvement in walking distance of 26 meters and an average improvement of 40 meters, representing a statistically significant 13% improvement ...

PAD is considered the first and most frequent manifestation of cardiovascular disease in patients with diabetes. There are few therapeutic and interventional options for patients ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...